To analyze the potential role of colchicine monotherapy in patients with tumor necrosis factor receptor associatedperiodic syndrome (TRAPS) in terms of control of clinical and laboratory manifestations. Methods. Patients with TRAPS treatedwith colchicine monotherapy were retrospectively enrolled; demographic, clinical and therapeutic data were collected andstatistically analysed after having clustered patients according to different times at disease onset, penetrance of mutations,dosage of colchicine, and different disease manifestations. Results. 24 patients (14 males; 15 with pediatric disease onset) treatedwith colchicine monotherapy were enrolled. Colchicine resulted in a complete response in 3 (12.5%) cases, partial response in 14(58.3%) patients, and lack of response in 7 (29.2%) patients. There were not significant differences in colchicine responsebetween pediatric and adult disease onset (p = 0:42), between low- and high-penetrance mutations (p = 0:62), and according todifferent dosages (p = 0:66). No significant differences were identified in the frequency of specific disease manifestations betweenpatients experiencing any response to colchicine and patients with lack of response. Conclusions. Colchicine monotherapy isuseful in a low percentage of TRAPS patients; nevertheless, it could be attempted in patients with milder phenotypes and at alower risk of developing reactive amyloidosis.
|Numero di pagine||6|
|Rivista||Mediators of Inflammation|
|Stato di pubblicazione||Published - 2020|
All Science Journal Classification (ASJC) codes
- Immunology and Allergy